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Introduction: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor
outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia
caused by serotype-specific P. aeruginosa in critically ill patients under appropriate antimicrobial therapy management.
Methods: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with
confirmed nosocomial pneumonia caused by P. aeruginosa. Patients were analyzed for a period of 30 days from time of
nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a phase IIa studyconducted at the
same time/centers were included in the prevalence calculations but not in the clinical outcome analysis.
Results: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). Serotypes with a
prevalence of less than 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes, 19%
mortality, 70% clinical resolution, 11% clinical continuation, and 5% clinical recurrence were recorded. Age and higher
APACHE II (Acute Physiology and Chronic Health Evaluation II) were predictive risk factors associated with probability of
death and lower clinical resolution for P. aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1
(40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes.
Persisting pneumonia with O6 and O11 was, respectively, 8% and 21%; clinical resolution with
O6 and O11 was, respectively, 75% and 57%.
Conclusions: In P. aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies
including larger group sizes are needed to correlate clinical outcome with virulence factors of P. aeruginosa in patients
with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the two serotypes most
frequently encountered in critically ill patients.Introduction
Pseudomonas aeruginosa is the pathogen responsible for
approximately 20% of ventilator-associated pneumonia
(VAP) and is one of the most difficult pathogens to treat
[1,2]. VAP caused by P. aeruginosa has the poorest out-
come of all intensive care unit (ICU) infections. Overall
mortality due to P. aeruginosa has been shown to be as
high as 70% [3,4], and directly attributable mortality
rates are approximately 40% [3,5].* Correspondence: qin.lu@psl.aphp.fr
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stated.Lipopolysaccharide (LPS) is an important virulence
factor in P. aeruginosa, exerting direct endotoxic effects.
The tripartite nature of LPS divides the molecule into a
hydrophobic lipid A region, a central core oligosacchar-
ide region, and a repeating polysaccharide portion re-
ferred to as O antigen or O polysaccharide [6,7]. The
most complete serotyping system for P. aeruginosa, the
International Antigenic Scheme (IATS), consists of 20
standard O serotypes [8,9]. Current epidemiology data
indicate that, of these 20 serotypes, IATS-O1, serogroup
2 (IATS-O2, IATS-O5, and IATS-16), IATS-O6, and
IATS-O11 are responsible for 70% of P. aeruginosa in-
fections [10,11].
The relationship between the virulence of P. aerugi-
nosa and different serotypes has been studied [12-14].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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secreted by the type III secretion system (TTSS), were
frequently serotyped as O11, whereas serotype O6
strains were associated with a negative ExoU phenotype
[12,15]. In an experimental model of pneumonia, sero-
type O11 was found to be associated with increased lung
injury [15]. Moreover, it has been reported that some se-
rotypes are able to induce high resistance of P. aerugi-
nosa to antibiotics [16-18].
Little is known, however, about the prevalence of P.
aeruginosa serotypes in nosocomial pneumonia and the
correlation between serotypes and clinical outcome. The
primary objective of the study was to assess the preva-
lence of P. aeruginosa serotypes in critically ill patients
with nosocomial pneumonia. The secondary objective
was to report clinical outcome of nosocomial pneumonia
caused by different serotypes of P. aeruginosa.Materials and methods
Study design and patients
This was a retrospective, multicenter, and non-interven-
tional epidemiological cohort study conducted between
2007 and 2009 in the ICU of nine hospitals in France,
Switzerland, and Belgium. Patients with confirmed hospital-
acquired pneumonia (HAP) and VAP caused by P. aerugi-
nosa were analyzed for a period of 30 days from the time of
diagnosis of pneumonia. The following ethics committees
approved the study: Basel Ethikkommission beider Basel
EKBB, Geneva Commission d’Éthique du Département de
Médecine, Hôpitaux Universitaires de Gèneve, Lausanne
Commission d’Éthique de la Recherche Clinique de la
Faculté de Biologie et Médecine, le Comité de Protec-
tion des Personnes, Ile de France-VI, Brussels Université
Catholique de Louvain, Faculté de Médecine, Commission
d’Éthique Biomédicale Hospitalo-Facultaire. Because it was
a retrospective epidemiological study, no informed consent
was needed. Written informed consent was obtained in
only 14 patients with serotype O11 HAP or VAP when they
were included in a phase IIa study [19].Inclusion criteria
Included patients were at least 18 years old, required in-
tensive care management with HAP and VAP, were ex-
pected to survive longer than 72 hours, and fulfilled one
of the following two criteria [20]:
1. Confirmed microbiological diagnosis of HAP and
VAP caused by P. aeruginosa isolated from lower
respiratory tract specimen with significant threshold
of at least 1 × 104 colony-forming units (CFU)/mL
for bronchoalveolar lavage (BAL) [21] or 1 ×
103 CFU/mL for protected mini-lavage (mini-BAL)
[22], or below if under treatment with antibiotics,and presence of a new or progressing pulmonary infil-
trate, plus one of the following three criteria: (a) fever
of greater than 38°C, (b) white blood cell count of
greater than 10,000/mm3, or (c) purulent sputum
Or
2. Confirmed microbiological diagnosis of HAP and VAP
caused by P. aeruginosa isolated from endotracheal
aspirate (ETA) with at least 1 × 106 CFU/mL and a
modified clinical pulmonary infection score (MCPIS)
of higher than 6 points [23].
Patients with nosocomial pneumonia caused by multiple
bacteria were included in the study. Multiple bacteria were
defined as more than one pathogen reaching significant
threshold isolated from lower respiratory tract specimen.Exclusion criteria
During the same period of time and at the same centers, a
phase IIa study which included 14 patients with O11 HAP
or VAP was performed [19]. To reflect the correct preva-
lence of O11 serotype during the observation period, these
patients were included in the prevalence calculation. They
were, however, excluded from the clinical outcome ana-
lysis as they were treated with a combination of standard
antibiotic treatment plus an adjunctive immunotherapy
[19]. Exclusion criteria were applicable to only the 14 pa-
tients who participated in the phase IIa study. They in-
cluded use of any investigational drug within 30 days prior
to study commencement or during the study; patients
with a known complement deficiency associated with
systemic lupus erythematosus, paroxysmal nocturnal
hemoglobinuria, hereditary angioedema, membranoproli-
ferative glomerulonephritis, collagen vascular disease, aut-
oimmune hepatitis, primary biliary cirrhosis, scleroderma,
or recurrent Neisserial infections; or patients with con-
firmed HIV infection. Transplant patients and/or patients
treated with systemic immuno-suppressive drugs (except
prednisone or prednisolone), patients with a known liver
function deficiency, and neutropenic patients (absolute
neutrophil count of less than 1,000 cells/μL) were also ex-
cluded [19].Assessments
Serotypes of P. aeruginosa isolated from lower respi-
ratory tract specimens were determined by agglutination
using serotype-specific antisera (Bio-Rad, Marnes-la
Coquette, France) in accordance with the instructions of
the manufacturer.
Patient clinical characteristics, Acute Physiology and
Chronic Health Evaluation II (APACHE II) score [24], se-
quential organ failure assessment (SOFA) score, MCPIS, risk
factors, microbiological assessments (including serotyping) in
ETA or BAL/mini-BAL, blood culture, chest radiographies,
Lu et al. Critical Care 2014, 18:R17 Page 3 of 9
http://ccforum.com/content/18/1/R17and laboratory parameters were assessed at inclusion. Scores,
laboratory parameters, chest radiographies, and body tempe-
rature were collected as frequently as possible from day 1 to
day 15, at days 21 and 30, or end of study (EOS) until patient
died or was lost for follow-up.
Data collected at day 30 or EOS, whichever date was
earlier, included clinical outcome, scores, laboratory pa-
rameters, chest radiographies, body temperature, dis-
charge from the ICU, and discharge from the hospital.
Clinical outcome was defined as follows:
 Continuation: clinical signs and symptoms of
pneumonia present during the whole assessment
period until day 30 (or EOS)
 Resolution: complete resolution of pneumonia signs
and symptoms present at the time of enrollment, no
new symptoms or complications attributable to the
pneumonia, no recurrence of pneumonia, and alive,
until day 30 (or EOS)
 Recurrence: return of all clinical signs and
symptoms of HAP/VAP, including infiltrates after
initial clinical resolution
 Death: assessment period until day 30 (or EOS).
Actual mortality was compared with predicted
mortality according to APACHE II score [24].
Microbiological outcome was defined as follows:
 Continuation: positive culture of P. aeruginosa in
ETA or (mini)-BAL over the whole assessment
period until day 30 (or E OS) associated with
persisting clinical signs and symptoms of pneumonia
 Resolution: baseline isolate not present in repeated
culture from original infection site
 Recurrence: isolation of P. aeruginosa from a culture
taken after the resolution of pneumonia
 Colonization: positive culture of P. aeruginosa in
ETA or (mini)-BAL over the whole assessment
period until day 30 (or EOS) without any clinical
pneumonia signs and symptoms.
Statistical analysis
Descriptive statistics were used for patient characteristics
and outcome variables. Categorical variables were expres-
sed as percentage, and continuous variables as mean ±
standard deviation or as median and 25% to 75% interquar-
tile range according to data distribution. Clinical and
microbiological outcomes were considered binary end-
points and these were analyzed by using Bayesian logistic
regression models. Logistic regression was used for binary
outcomes and model based P values, using likelihood ratio
tests. Time-to-event endpoints (survival and clinical and
microbiological resolution) were analyzed by using Kaplan-
Meier and Cox proportional hazards regression models.Analysis was done without adjustment for risk factors, with
adjustment for different serotypes, and with adjustment for
risk factors (age, APACHE II score, CPIS, SOFA score, and
adequacy of antibiotic treatment). Analyses of data were
performed by using R 2.10.1 and WinBUGS 1.4.3.
Results
Patient demographics and characteristics
Patients’ flow chart is shown in Figure 1. Of 143 patients,
123 patients were included in the prevalence analysis and
129 in the overall clinical outcome analysis. Among 123 pa-
tients with serotype available, 114 patients had VAP (93%)
and 9 had HAP (7%). Clinical and demographic data are
shown in Table 1. At pneumonia onset, median length of
hospital stay was 13 days, median length of ICU stay was
8 days, and median duration of mechanical ventilation was
8 days.
Prevalence of Pseudomonas aeruginosa serotypes
The rates of prevalence of serotypes were, respectively,
O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%).
The sum of all serotypes with a prevalence of less than
5% (PL5) was 13%, and 8% of all patients had a P. aeru-
ginosa infection classified as not typeable (NT) (Table 2).
The prevalence of P. aeruginosa serotypes in French
and Swiss investigator centers is shown in Figure 2. The
distribution of P. aeroginosa serotypes by each investiga-
tor site is shown in Table 3.
Overall clinical outcome
On day 30, across all serotypes, a 19% mortality, a 70%
clinical resolution, an 11% clinical continuation, and a
5% clinical recurrence were recorded. Mortality was as-
sociated with age (P = 0.012) and high APACHE II score
(P = 0.003). Clinical resolution was not associated with
any of the risk factors—APACHE II score, CPIS score,
SOFA score, adequate antibiotic treatment and age—or
interaction of risk factors. Clinical continuation was as-
sociated with high APACHE II score (P <0.001).
Time to death was associated with age (P = 0.015) and
high APACHE II score (P = 0.010). Time to event ana-
lysis of clinical resolution was associated with high APA-
CHE II score (P = 0.008).
Among 102 patients with microbiological information
available, a 41% microbiological resolution, a 25% micro-
biological continuation, a 23% colonization, and an 11%
microbiological recurrence were recorded. Time to micro-
biological resolution was associated with APACHE II score
(P <0.001) and higher MCPIS (P <0.007).
Clinical outcome according to Pseudomonas aeruginosa
serotype
Among 109 patients (Figure 1), 15% of patients had
nosocomial pneumonia caused by multiple bacteria,
Figure 1 Patients’ flow chart. O11, serotype O11; PA, Pseudomonas aeruginosa.
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type groups. An 18% mortality and a 69% clinical reso-
lution were recorded. The highest mortality rate was
observed in patients with serotype O1 infections (40%),
and the lowest in patients with serotype O2 infections
(0%) (Figure 3). Actual mortality and predicted mortality
by APACHE II score were similar in patients infected by
serotypes O1, O10, and O11, whereas actual mortality
was lower than predicted mortality in patients infected
by serotypes PL5, O6, NT, and O2 (Figure 3).Table 1 Clinical characteristics of patients with nosocomial pn
serotypes (n = 123)
Serotypes All O1 O2
VAP/NP, n (%) 114/123 (93) 9/10 (90) 10/11 (91)
Age, years 61 (43 to 72) 65 (56 to 74) 63 (58 to 70)
Male% 75 40 73
Antibiotics at pneumonia
onset, n, %
84 (68) 5 (50) 8 (73)
Inappropriately treated % 11 0 0
MCPIS 7.0 (5.0 to 9.0) 8.0 (5.8 to 9.5) 9.0 7 to 10)
APACHE II score 17 (12 to 22) 17 (11 to 29) 15 (11 to 17)
SOFA score 7.0 (5.0 to10.0) 9.5 (6.5 to 15.0) 5 (4 to 7)
Hospital length of stay
at inclusion, days
13 (7 to 14) 14 (8 to 45) 8 (4 to 18)
ICU length of stay at
inclusion, days
8 (4 to 17) 11 (4 to 17) 5 (3 to 12)
Duration of mechanical
ventilation at inclusion, days
8 (5 to 17) 10.5 (7 to 17) 5 (3 to 12)
Data are expressed as median and 25%-75% interquartile. Nosocomial pneumonia
nia (VAP). APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intens
able; PL5, sum of all serotypes with a prevalence of less than 5%; SOFA, sequentialAs shown in Figure 4, the highest clinical resolution
rate was found in patients with serotype O2 (82%) and
the lowest in patients with serotype O1 (40%). The sero-
types O1, O10, O11, and NT had lower rates of clinical
resolution (40%, 58%, 57%, and 60%) and higher rates of
continuation (20%, 17%, 21%, and 30%), whereas the se-
rotypes O6 and the PL5 group had continuation rates
below 10%. The highest rates of recurrence were found
in patients with serotype O1, whereas none of the 11 pa-
tients with serotype O10 and PL5 relapsed.eumonia caused by different Pseudomonas aerugionsa
O6 O10 O11 PL5 NT
35/36 (92) 10/12 (83) 26/28 (93) 15/16 (94) 9/10 (90)
57 (39 to 67) 59 (40 to 77) 65 (42 to 78) 64 (47 to 71) 64 (59 to 72)
81 92 68 81 80
28 (78) 12 (100) 13 (46) 12 (75) 6 (60)
14 8 14 6 0
7 (5 to 8) 6 (4 to 8) 8.5 (7 to 9.5) 7.5 5 to 9) 6.0 (4 to 8)
17 (11to 23) 17 (11 to 29) 17 (14 to 20) 19 (12 to 26) 16 (12 to 19)
7 (5 to 10) 9.5 (6.5 to 15.0) 6.0 (4.5 to 8.0) 7 (6.0 to 9.0) 6.0 (4.0 to 9.2)
12 (7 to 25) 13 (8 to 19) 18 (8 to 34) 12 (6 to 24) 14 (8 to 25)
7 (5 to 19) 8 (3 to 13) 9 (6 to 19) 8 (4 to 15) 9 (5 to 14)
8 (5 to18) 9 (4 to 13) 9 (5 to 17) 8 (4 to 15) 9 (6 to 14)
(NP) includes hospital-acquired pneumonia and ventilator-associated pneumo-
ive care unit; MCPIS, modified clinical pulmonary infection score; NT, not type-
organ failure assessment.
Table 2 Pseudomonas aeruginosa serotype distribution
(n = 123)
Serotype Number Prevalence, percentage
O6 36 29.3
O11 28 22.8
O10 12 9.8
O2 11 8.9
O1 10 8.1
NT 10 8.1
O3 5 4.1
O4 3 2.4
O7 3 2.4
O9 2 1.6
O8 1 0.8
O12 1 0.8
O15 1 0.8
Serotypes with a prevalence of more than 5% are expressed in boldface. NT,
not typeable.
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pneumonia was 11.4 days (Table 4). Overall time to
resolution was 12.1 days, the shortest being for the pa-
tients with O2 infections (10 days) and longest being for
the patients with O11 infections (13.4 days) (Table 4).Discussion
Our study shows that, of the 20 different serotypes of P.
aeruginosa, O6 (29%) and O11 (23%) were the most
prevalent serotypes, responsible for the majority of noso-
comial pneumonia. Across all serotypes, clinical out-
come correlates strongly to APACHE score. Mortality
and clinical resolution tend to be worse in patientsSerotypes
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Figure 2 Pseudomonas aeruginosa serotype distribution in
French (black bars) and Swiss (grey bars) investigator centers.
n, number of patients.infected by P. aeruginosa serotype O1 and better in
patients infected by serotypes O2 and NT and O6.
Prevalence of Pseudomonas aeruginosa serotypes
While the prevalence of P. aeruginosa serotype varies
from one hospital to another and from one country to
another, O6 and O11 are often the most prevalent sero-
types reported in previous studies [10,14,25-30]. It
should be pointed out that the prevalence of P. aerugi-
nosa serotypes reported in previous studies was obtained
either from multiple infectious sites or from a single
hospital or country. To the best of our knowledge, our
study is the first assessing the prevalence of P. aerugi-
nosa serotypes in nosocomial pneumonia from different
hospitals of different countries.
Although the prevalence of serotypes is different among
the countries and investigator sites (Figure 2 and Table 3),
the overall rates of prevalence of the most common P. aer-
uginosa serotypes observed in patients with nosocomial
pneumonia were O6 and O11. After exclusion of the lar-
gest enrollment site from the analysis, O6 and O11 remain
the most prevalent serotypes, suggesting that investigator
site effect does not influence interpretation of the finding.
This result is comparable with those previously reported
in the literature [10,15,25,26,28]. In approximately 8% of
cases, the standard method failed to detect serotype be-
cause of self-agglutinating or non-agglutinating strains and
the samples were classified as “not typeable”. This propor-
tion is less than those previously reported [11,18,27].
Clinical outcome and Pseudomonas aeruginosa serotypes
Age and APACHE II score were found to be the predict-
ive risk factors for nosocomial pneumonia caused by
P. aeruginosa. This result indicates that mortality and
clinical and microbiological resolutions were strongly cor-
related with severity of the patients at the initial phase of
pneumonia [31-33].
The relationship between virulence of P. aeruginosa
and different serotypes has been investigated in a few
studies [12-14]. It has been shown that clinical strains
lacking B-band O antigen increase TTSS and virulence
[34]. On the other hand, it was found that strains secret-
ing ExoU were frequently serotyped as O11 [12,15].
ExoU is one of the toxins secreted by TTSS and contrib-
utes to epithelial cell toxicity, lung injury, and sepsis in
infected animals [35,36]. Exo S and Exo T disrupt the
host cell actin cytoskeleton, block phagocytosis, and are
associated with mortality in animal models [37]. Further-
more, TTSS is associated with persistent VAP caused by
P. aeruginosa and poor clinical outcome [38,39]. Faure
et al. reported that, among 13 P. aeruginosa O1 strains,
7 secreted Exo S [12]. Recently, Le Berre et al. showed
that the O11 serotype, elastase production, and TTSS
were associated with increased lung injury in a murine
Table 3 Pseudomonas aeruginosa serotype distribution by each investigator site
Investigator site O1 O2 O6 O10 O11 PL5 NT Total
1 n 2 0 8 2 1 2 1 16
% 12.5% 0.0% 50.0% 12.5% 6.3% 12.5% 6.3% 100%
2 n 1 0 3 2 2 3 2 13
% 7.7% 0.0% 23.1% 15.4% 15.4% 23.1% 15.4% 100%
3 n 2 4 12 1 14 4 3 40
% 5.0% 10.0% 30.0% 2.5% 35.0% 10.0% 7.5% 100%
4 n 0 0 3 1 3 1 2 10
% 0.0% 0.0% 30.0% 10.0% 30.0% 10.0% 20.0% 100%
5 n 1 1 5 0 1 2 0 10
% 10.0% 10.0% 50.0% 0.0% 10.0% 20.0% 0.0% 100%
6 n 4 5 4 1 2 2 0 18
% 22.2% 27.8% 22.2% 5.6% 11.1% 11.1% 0.0% 100%
7 n 0 1 1 5 1 2 2 12
% 0.0% 8.3% 8.3% 41.7% 8.3% 16.7% 16.7% 100%
Investigator sites with more than 10 patients were analyzed. Percentages of serotype are expressed in boldface. NT, not typeable; PL5, sum of all serotypes with a
prevalence of less than 5%.
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strains were significantly more virulent than non-
typeable strains and serotype O6; O11 strains were asso-
ciated with a positive (ExoU) phenotype, whereas O6
strains were associated with negative ExoU phenotype
[12,15]. These results suggest that clinical outcome of
patients with pneumonia caused by P. aeruginosa could
be related to serotypes.
This article reports on the first ever study to assess
the clinical outcome of nosocomial pneumonia causedSerotypes
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Figure 3 Percentages of predicted and actual mortality of
patients with nosocomial pneumonia caused by different
Pseudomonas aeruginosa serotypes. Black bars indicate actual
mortality, and white bars indicate predicted mortality estimated
according to Acute Physiology and Chronic Health Evaluation II
(APACHE II) score. NT, not typeable; PL5, sum of all serotypes with a
prevalence of less than 5%.by a range of different serotypes of P. aeruginosa in
critically ill patients under standard ICU management.
Interestingly, the results show that the mortality rates
for serotypes O1, O10, and O11 were in line with the
expected mortality rates estimated by the severity of the
patients (APACHE II score). Infections with serotypes
O6, O2, and NT serotypes, however, had lower mortality
than expected. There was a trend toward poorer
outcome of patients with pneumonia caused by sero-
types O1.Serotypes
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Figure 4 Proportions of death (black bars), persisting
pneumonia (or continuation) (red bars), and clinical resolution
(green bars) of patients with nosocomial pneumonia caused by
different Pseudomonas aeruginosa serotypes. NT, not typeable;
PL5, sum of all serotypes with a prevalence of less than 5%.
Table 4 Mean time to death and mean time to clinical resolution
Serotypes Death/re-solution O1 O2 O6 O10 O11 PL5 NT
Time to death in days, mean ± SD (n = 20) (n = 4) (n = 0) (n = 6) (n = 3) (n = 3) (n = 3) (n = 1)
11.4 ± 7.4 12.0 ± 8.1 NA 10.2 ± 7.1 16.0 ± 7.2 12.3 ± 4.2 8.3 ± 4.0 7
Time to clinical resolution in days, mean ± SD (n = 75) (n = 4) (n = 10) (n = 28) (n = 7) (n = 8) (n = 12) (n = 6)
12.1 ± 5.9 11.0 ± 5.8 9.9 ± 4.0 11.6 ± 6.1 13.1 ± 4.3 13.4 ± 7.2 13.3 ± 5.9 10.8 ± 4.1
NT, non typeable; PL5, sum of all serotypes with a prevalence of less than 5%; SD, standard deviation.
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one can see that, while the O6 serotype is the most
prevalent (29%), it has lower levels of continuation (8%)
and death (17%) and higher resolution rates (75%) than
the second most prevalent serotype O11 (prevalence
23%, continuation 21%, death rate 21%, and resolution
57%). This finding could be explained by the absence of
ExoU with serotype O6 and presence of ExoU with sero-
type O11 as previously reported [15]. Consequently,
compared with O6, O11 may be a more clinically rele-
vant target for therapy in terms of patient outcomes
[19]. Further study with larger groups is required in
order to draw firm conclusions.
Methodological limitations
First, the prevalence obtained from our study may not
be applied globally, because of an absence of data from
additional countries known for their high prevalence of
pneumonia caused by P. aeruginosa, such as Spain, Italy,
Greece, the US, Mexico, Canada, and Japan. Serotypes
may also vary from hospital to hospital within a given
country and within the same hospital when assessed at
different times. The most prevalent serotypes obtained
in our study are, however, comparable to those previ-
ously reported in the literature. Second, the potential re-
lationship between serotypes, virulence factors, and
antibiotic resistance was not studied. Patients hospital-
ized in the same ICU could have a P. aeruginosa clone
with the same virulence. Moreover, P. aeruginosa strains
with the same serotype could be different clones exhibit-
ing different virulence. Third, interpreting the results on
clinical outcome is limited due to the small size of the in-
dividual serotype groups. However, these preliminary data
provide relevant information for further investigations.
Further larger clinical study combining clinical out-
come with distribution of virulence factors by serotypes
and identification of specific clones by pulsed-field gel
electrophoresis is needed to enhance the implication of
these clinical findings [40].
Conclusions
O6 and O11 are the most prevalent serotypes in nosoco-
mial pneumonia caused by P. aeruginosa. Mortality
tends to be worse with O1 and better with O2; clinical
resolution tends to be better with O2 and O6 comparedwith other serotypes, but it is difficult to draw firm con-
clusions given the small number of strains in each sero-
type group. Further large-powered multicenter study is
required to assess clinical outcome of nosocomial pneu-
monia caused by P. aerginosa serotypes, particularly O6
and O11, the two serotypes most frequently encountered
in critically ill patients.
Key messages
 In Pseudomonas aeruginosa nosocomial pneumonia,
the most prevalent serotypes are O6 and O11.
 Across all serotypes, mortality and clinical resolution
of pneumonia correlate strongly to APACHE score.
 Clinical outcome tends to be worse with serotype
O1 and better with O2, but a firm conclusion needs
a larger group size.
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